Pyruvate is one of the key metabolites of canonical glycolysis in cytosol, which connects the glucose oxidative phosphorylation in mitochondria, and produced from the lactate oxidation by lactate dehydrogenase (LDH-B) in addition to the transamination reaction from amino acids, including alanine (Figure 1). Pyruvate also suppresses the stimulated sorbitol pathway in diseases, such as diabetes, reducing the NAD⁺ consumption and preserving the NAD⁺/NADH (NAD⁺ reduced form) ratio (Figure 1). Additionally, pyruvate promotes oxidative phosphorylation, reconverting NADH to NAD⁺ in electron transport chain and producing ATP in mitochondria. The NAD⁺/NADH constitutes one of coenzyme redox potentials involved in a wide range of crucial enzymatic reactions. Therefore, the NAD⁺ depletion brings to metabolic alterations and organ dysfunction in diseases and aging. Alternatively, NAD⁺ is also synthesized from its precursors: nicotinamide (NAM), nicotinamide mononucleotide (NMN), or niacin (NA, Vitamin B3) and related derivatives, such as nicotinamide riboside (NR), by the NAD⁺ salvage pathway and/or their exogenous supplements. These large molecules as well as Metformin, Rapamycin, and Resveratrol are amongst sirtuin-activating compounds. In this respect, there have been many systematic detailed reviews in NAD⁺ biomedical effects on diseases and healthy aging, but the following works are robustly of clinical relevance.

NAD⁺ plays a critical role in DNA repair, via the poly (ADP-ribose) polymerase (PARP) and the sirtuins (SIRT1–7) signal pathways, cellular energy metabolism, and survival in addition to redox reactions. In 2017, Sinclair et al first demonstrated the speculation of the new role that NAD⁺ directly regulates protein–protein interactions in damaged DNA repairing in the view of cell level. The NAD⁺ level in the liver...
was decreased with aging and the NMN treatment (500 mg/kg/day) for a week enhanced hepatic NAD$^+$ concentrations in old mice back to those in young ones (6 vs 22 months); the reduced PARP1 activity in the old mice was also restored by the treatment. Further, a single oral dose of NMN (2000 mg/kg/day) for 8 days significantly improved blood metrics in old and young (23 vs 4 months) mice subjected to the gamma irradiation.7 Furthermore, in human primary fibroblast cells, the NMN treatment also declined the phosphorylated Histone H2AX ($\gamma$H2AX, a DNA damage protein marker) and reduced DNA fragmentation, protecting from Paraquat (a poisonous herbicide)-induced DNA damage.7 These results strongly indicate that NMN efficiently protected against the radiation exposure and reduced the adverse effect of chemotherapy, preventing from DNA damage and aging (restoring 2 years old mice to their physical state at a half year), nearly turning a 60 old man back to 20. This novel finding that was recognized by several Nobel laureates encouraged numerous studies, in vitro and in vivo, substantiating that NAD$^+$ and its precursors are apparently beneficial in preserving organ metabolism and function and postponing aging in animal models as well as patients.8-11

However, many clinical trials with NAD$^+$ or its precursors (NMN, NA, NR) showed the indefinite clinical outcomes in past years.12 Newly, the first clinical test with oral Niacin (NA) displayed remarkable salutary effects on patients with mitochondrial myopathy. With a 10-month therapy, blood NAD$^+$ increased up to 8-fold and muscle strength and mitochondrial biogenesis enhanced in all subjects. Patients’ muscle NAD$^+$ reached the level of controls and muscle metabolome also shifted toward normal along with liver fat decreased even 50%.13 The result was considered advantages of NA over NMN in raising NAD$^+$ in humans. Alternatively, data reviewed from 8 randomized controlled trials showed that the NA supplementation improved the blood lipid profile, however, did not affect plasma glucose and hemoglobin A1c levels in Type 2 diabetic patients.14 Nevertheless, a recent study provided a negative result of NR effects on lifespan in both male and female mice at the doses tested.15

A recent important finding is that the plasma levels of extracellular nicotinamide phosphoribosyltransferase (eNAMPT), a key NAD$^+$ biosynthetic enzyme located in extracellular vesicles (EVs), were declined with age in both mice and humans, injuring function of specific tissues.
EV-contained eNAMPT could be internalized into cells and directly enhanced NAD$^+$ biosynthesis. Supplementation with EV-contained eNAMPT enhanced wheel-running activities and extended lifespan in aged mice. The results further confirmed the NAD$^+$ key role in healthy aging and provided a novel possibility that the pharmaceutical intervention to increase eNAMPT levels may preserve healthy aging in humans.

Albeit several clinical trials showed positive outcomes, questions still rise from supplements with NAD$^+$ and its precursors in several aspects, such as administration routes, enteral absorption, intracellular biosynthesis and transference in various cell types. Table 1 summarizes some clinical advantages relative to NAD$^+$ and senolytics in healthy aging.

### Table 1. Pyruvate clinical advantages relative to NAD$^+$ and senolytics in healthy aging.

| MAIN UNDERLYING MECHANISMS | REFERENCES | CLINICAL STUDIES | REFERENCES |
|-----------------------------|------------|------------------|------------|
| NAD$^+$ Improving most enzymatic reactions | Katsyuba et al,$^1$ Kang et al,$^2$ Covarrubias et al,$^4$ Bonkowski and Sinclair$^5$ | IV NAD$^+$ infusion with safety | Grant et al$^3$, Rutherford et al$^9$ |
| NA/NAM/ Promoting energy metabolism | Katsyuba et al,$^1$ Kang et al,$^2$ Covarrubias et al,$^4$ Bonkowski and Sinclair,$^5$ Iannetti et al$^{68}$ | NA: mitochondrial myopathy | Pirinen et al$^{13}$ |
| NMN/NR Inhibiting oxidative stress and inflammation | Katsyuba et al,$^1$ Kang et al,$^2$ Covarrubias et al,$^4$ Bonkowski and Sinclair,$^5$ Iannetti et al$^{68}$ | NAM: acute kidney injury | Poyan Mehr et al$^11$ |
| Repairing DNA damage | Li et al$^7$ | Controversial outcomes | Radenkovic et al$^{12}$ Xiang et al$^{14}$ Harrison et al$^{15}$ |
| Senolytics Inhibiting the SASP | Sabbatinelli et al,$^{20}$ Baker et al,$^{21}$ Gil and Withers,$^{25}$ Farr et al$^{23}$ | Idiopathic pulmonary fibrosis | Justice et al$^{24}$ |
| AP20187 Eliminating senescent cells | Sabbatinelli et al,$^{20}$ Baker et al,$^{21}$ Gil and Withers,$^{25}$ Farr et al$^{23}$ Lehmann et al,$^{28}$ Xu et al$^{29}$ | Systemic sclerosis | Martyanov et al$^{26,27}$ |
| Dasatinib/ | | | |
| Quercetin | | | |
| Fisetin | | | |
| Sodium Raising NAD$^+$/NADH ratio | Zhang et al$^4$ | Heart failure | Schilling et al$^{49}$ |
| Pyruvate Preserving glycolytic pathways | Zhang et al$^4$, Gou et al$^{50}$ | Liver cirrhosis | Mateva et al$^{50}$ Petkova et al$^{51}$ |
| Reactivating PHD activity/OXPHOS | Zhang et al$^4$, Ksiezak-Reding et al$^{62}$ Stacpoole$^{63}$ | Diabetes | Petkova et al$^{52}$ Inoue et al$^{53}$ |
| Correcting severe metabolic acidosis | Wang et al$^5$, Hu et al$^{41}$ Flaherty et al$^{42}$ | Mitochondropathy | Li et al$^{44}$ Koga et al$^{54}$ Battaglia et al$^{74}$ |
| Exerting anti-oxidative, anti-inflammatory | Liu et al$^{43}$ | Skin; dermal fibroblasts | Han et al$^{47}$ Kim et al$^{47}$ |
| Inhibiting apoptosis and senescence | Zhang et al$^{45}$ Kaplon et al$^{46}$ Olenchock and Vander Heiden$^{66}$ | Leigh syndrome fibroblasts | Iannetti et al$^{58}$ |
| Protecting mitochondria | Koga et al$^{44}$ Kim et al$^{67}$ Battaglia et al$^{74}$ | Covid-19? | Zhou$^{75}$ |
| Repairing DNA damage | Han et al$^{47}$ McGowan and Bucher$^{70}$ Chenoufi et al$^{71}$ | Long-term stable solutions | Zhou$^{48}$ Zhou$^{75}$ |
| | | Without adverse effects | Schilling et al$^{49}$ Mateva et al$^{50}$ Zhou$^{75}$ |

**Abbreviations:** NA, niacin; NAD$^+$/NADH, nicotinamide adenine dinucleotide (oxidized/reduced form); NAM, nicotinamide; NMN, nicotinamide mononucleotide; NR, nicotinamide riboside; OXPHOS, oxidative phosphorylation; PDH, pyruvate dehydrogenase; SASP, senescence-associated secretory phenotype.
types, drug dose, and treatment period to contribute NAD⁺ homeostasis as well as adverse effects.⁵,¹²,¹⁷

The preliminary clinical investigation of intravenous (IV) NAD⁺ in healthy males was first documented for its pharmacokinetic properties in 2019.¹⁸ It was just a case report regarding the clinical valuable effect of IV NAD⁺ on a patient subjected with Parkinson’s disease to date,¹⁹ though IV Diprophosphorydine nucleotide (DPN) and NAD(P)H were revealed with salutary clinical effects 3 decades ago. In addition, IV NAD⁺ for healthy aging, which cannot be orally administrated due to the degradation, is expensive. It also requires a slow infusion for several hours with mild adverse effects. Current studies indicate that clinical effects of NAD⁺ and its precursors for diseases and healthy aging are still controversial, requiring further validation with high quality and large scale randomized controlled trials.

**Senolytics in Healthy Aging**

On the other hand, it has been demonstrated for decades that cellular senescence promotes aging with tissue NAD⁺ decline.²⁰ Senescence cells, that is, cells at a stress-induced irreversible growth arrest: naturally generated “zombie cells” in life, but actually are metabolic active with more glycolytic state mimic to cancer cells. The accumulation of these cells in various tissues and organs over time is speculated to intimately associate with organ dysfunction, diabetes, tumorigenesis, and aging. It was van Deursen et al who first demonstrated that clearance of senescence cells by AP20187, one of senolytics, preserved multiorgan (kidney and heart) function and extended healthy lifespan about 25% (17%-35%) in both male and female mice of 2 tiorgan (kidney and heart) function and extended healthy lifespan. It was lately identified about 25% (17%-35%) in both male and female mice of 2,²¹,²² It was lately identified that both estrogen deficiency and cellular senescence are independent factors in osteoporosis of aged women.²³

The first human pilot study with oral senolytics (Dasatinib plus Quercetin, DQ) on 14 elderly patients subjected with idiopathic pulmonary fibrosis (IPF with moderate to severe severity) was released by Justice et al in early 2019.²⁴ The DQ treatment over 3-weeks robustly enhanced physical function (6-minutes walk distance, 4-m gait speed, and chair-stands time) with clinical meaningful alterations though pulmonary function tests were not improved. However, correlations were shown between changes in physical function and senescence-associated secretory phenotype (SASP) factors’ expression.²⁴ IPF is a disease associated with senescent cell accumulation in lungs that is irreversible with aging and fatal. These preliminary results evidently indicated the potential and feasibility that intervention with senolytics ameliorated, at least in part, consequences of aging-related diseases in humans, as demonstrated in mice and human cells with IPF, in vitro.²⁵

A retrospective investigation of subjects with systemic sclerosis accompanied by fibrotic interstitial lung treated by senolytic Dasatinib (D) for 9 months was reported in 31 patients with drug well-tolerance. Of them, 65% showed no progression of lung fibrosis and 36% had no progression of total interstitial lung diseases; 12 patients were available with skin gene expression signature before and after the treatment.²⁶ Soon, reexamination of these 12 patients discovered that the SASP gene expression and its degree were significantly decreased in 3 clinical improvers, compared to 9 non-improvers after the treatment.²⁷ The results are also consistent with the attenuation by DQ treatments in the experimental lung fibrosis and senescent cell transplant in mice.²⁸,²⁹

These clinical pilot studies are considered an unprecedented breakout in the anti-aging area in humans. The second clinical report from Mayo Clinic further illustrated that oral senolytics DQ treatment decreased senescent cells abundance in 9 diabetic patients, as shown by a decrease of cells with senescent markers: p16INK4A-, p21CIP1-expression and SAβgal activity and adipocyte progenitors with reduced replicative potential. Also, abdominal skin epidermal p16INK4A-, p21CIP1-expressing cells were attenuated, as were blood SASP factors, like IL-1α, IL-6, etc.³⁰ These improvements were consistent with findings that the DQ therapy reduced insulin resistance, proteinuria, and renal podocyte dysfunction in obesity mice.³¹ Both strongly indicate that cellular senescence is a causal factor in initiation and progression of obesity/diabetes kidney diseases and senolytic agents hold benefits in treating obesity/diabetes-related metabolic dysfunction and its complications. Recently, senotherapeutics (senolytics and senomorphics) has been greatly focused on various diseases in animal and clinical studies.³²,³³,³⁴,³⁵ Quercetin with multi-therapeutic benefits is now advocated in the Covid-19 treatment.³⁶,³⁷ Elderly people, especially those with comorbidities shows severity and high mortality in Covid-19 pandemic. The virus may efficiently display enhanced replication in senescent cells, indicating that the accumulation of senescent cells with aging and age-related diseases may play a role in the severity in old people and senotherapies may improve the clinical outcome and efficacy of vaccinations of Covid-19 virus infection.³⁸,³⁹ A new striking finding in old mice demonstrated that senolytic drugs before or after the Covid-19 virus exposure significantly reduced cellular senescence, leading to increased anti-viral antibodies and declined mortality,⁴⁰ evoking an additive therapeutic approach in elderly with Covid-19 viral infection.

Following the senolytic therapy, the second generation of commercial products as dietary supplements for healthy aging: Synext has been brought to nutrition markets, which modified the first generation of anti-aging products: Niacin (NA) and NAM (both are NAD⁺ precursors) with senolytics and other antioxidants, including Resveratrol, Curcumin, and Q10 in a total of 15 components. However, no clinical research substantiated the reality that Synext, alone or in combination with NAD⁺, prolong lifespan in healthy humans at present. It is just one of dietary supplements in nutrition markets.
**Pyruvate in Healthy Aging**

The commercial products for healthy aging are now becoming popular in nutrition markets, but their prevailing may be limited due to uncertain efficacy, side effects, and cost, such as Niacin Flush from Synext in nutrition markets. One among potent competitors is sodium pyruvate that holds all merits of current commercial anti-aging products in markets. As mentioned above, exogenous pyruvate spontaneously and directly generates NAD⁺ via the LDH reductive reaction free of energy, raising intracellular NAD⁺ levels on the equal molecular basis (Figure 1).

Pyruvate outstanding pleiotropic features mainly are (1) enhancement of cellular hypoxia tolerance, reversal of glycolytic disorder (Warburg effect) by preserving glycolysis, via the enhancement of NAD⁺/NADH ratio, and promoting oxidative phosphorylation with reactivation of pyruvate dehydrogenase (PDH) activity, leading to reversal of lethal hypoxia lactic acidosis and the Warburg effect,⁴,⁴¹,⁴³ (2) potent duel (direct and indirect) anti-oxidative/nitrosative stress and -inflammation to inhibit inflammatory mediators and cytokines secretion and inflammatory cells infiltration,⁴²,⁴³ and (3) protection of mitochondrial structure and endoplasmic reticulum function as well as against cellular apoptosis and so on.⁴⁴,⁴⁵ Therefore, pyruvate protects against multiorgan (especially vital organs) dysfunction and improves survival in a diversity of pathogenic injuries, including cardiac, hemorrhagic, traumatic, and septic shock, liver cirrhosis, diabetes, neurodegenerative diseases, mitochondriopathy, and even cancer and aging; clinically, several reports demonstrated pyruvate therapeutic effectiveness and safety in various diseases as well as skin injuries.⁴⁶-⁵⁴

Early studies discovered that oxidative/nitrosative stress induces DNA damage. The PARP activation or NAD⁺ depletion retards the repairing DNA damage. It was also demonstrated that pharmacological restoration of NAD⁺ by using exogenous pyruvate, NAD⁺, or NAM, attenuated neuronal death with Zn²⁺-induced injuries in mice in vitro and in vivo.⁵⁵ Pyruvate not only generates NAD⁺, but also inhibits the PARP activation, as evidenced that systemic pyruvate prevented loss of total NAD⁺ content and PARP activation in addition to inhibition of oxidative stress, protecting brain and liver function in swine subjected to severe hemorrhagic shock.⁵⁶

It was found a decade ago that exogenous pyruvate prevented aging of mouse oocytes though NAD⁺ and senescence were not concerned in the investigation.⁵⁷ As mentioned above, NAD⁺ and eNAMPT are declined with aging, aging compromised NAMPT-mediated NAD⁺ biosynthesis, leading to the pathogenesis of Type 2 diabetes; NMN, a product of the eNAMPT reaction and a key NAD⁺ precursor, could be effective intervention of age-induced diabetes in mice.⁵⁸ Similarly, oral pyruvate simply raised kidney NAD⁺ and attenuated diabetic nephropathy in diabetic mice.⁵⁹ Further, a recent finding showed that the late-onset caloric restriction for 14 days in middle-aged rats, other than young ones, altered skeletal muscle metabolism by modulating pyruvate metabolism from glycolysis to oxidative phosphorylation with normalized muscle mass.⁶⁰ Furthermore, chronic sodium pyruvate supplementation with experimental chow for 6 months improved brain metabolism, proving benefits in aging-related cognitive dysfunction and inactivity although the NAD⁺ level and cellular senescence were not determined, in young and middle-aged mice.⁶¹ Notably, pyruvate has been demonstrated to preserve energy metabolism and function of matured red blood cells (RBCs) without cellular nucleus and mitochondria, the maximum tissue volume in humans,⁶²,⁶³ strongly indicating its survival protection of each individual cell throughout the body in hypoxia or even anoxia. Alternatively, it has been long recognized that the PDH activity is closely pertained in healthy aging and age-related diseases contributed from disturbances of mitochondrial bioenergetics homeostasis,⁶²,⁶³ while pyruvate is one of PDH activators, as dichloroacetate (DCA),⁴,⁵ to reactivates the suppressed PDH activity.⁶⁴ Importantly, it was first demonstrated several years ago that driving pyruvate oxidation via increase of PDH activity can abrogate tumor growth in BRAF-driven melanoma cell lines by prompting oncogene-induced senescence, a critical defense against tumor progression.⁶⁵,⁶⁶ Therefore, pyruvate also shows its anti-tumor properties in animals as evidenced by DCA.⁶⁸

These early studies implied that equal to endogenous pyruvate as the key metabolite of glucose metabolism, exogenous one can modulate glucometabolic disorders, specially reverse the Warburg effect predominantly as a PDH stimulator and anti-oxidative, -inflammatory agent to facilitate prolongation of lifespan in healthy aging, as indicated in diabetic mice.⁴,⁶³

A recent cell investigation demonstrated that pyruvate deprivation induced mitochondrial alterations and cellular senescence in normal human dermal fibroblasts in normal cell cultures; exogenous pyruvate protected against cellular senescence in normal fibroblasts with raising NAD⁺ generation, in vitro.⁶⁵ Further, pyruvate augments anti-aging phenotypes in skin equivalents, which closely mimics human skin, in vivo. The results showed that pyruvate inhibited senescence-associated β-galactosidase staining and expressions of SASP genes and protected mitochondria in the cells.⁶⁷ These data strongly suggest that pyruvate as both an antisenescence metabolite and a NAD⁺ substitute may improve natural aging and aging-related diseases in consistence with prior findings that did not monitor cellular senescence mentioned above.

In another cell study, galactose-induced death of Leigh syndrome (mitochondrial complex I deficiency) patient’s fibroblast cells can be rescued by both exogenous pyruvate and NAD⁺ with different metabolic and molecular mechanisms. Notably, pyruvate is more efficient in the fibroblast cell viability than NAD⁺ (1.0-10.0 mM) on an equimolar basis against galactose-induced death.⁶⁸ Although both pyruvate and NAD⁺ increased the cellular NAD⁺ levels to a different extent,
pyruvate-induced rescue of the cell death was not primarily mediated by the raised NAD+. The results displayed more potent anti-oxidative stress of pyruvate relative to NAD+; while less ATP generation with pyruvate compared to NAD+ in rescuing the cell death, though the cellular senescence was not detected in the study.68 These data probably indicate that pyruvate owns a stronger capacity to repair DNA damage compared to equimolar NAD+. Alternatively, it was early shown in a specific simple setting of cell experiments that both exogenous pyruvate and NAD in 2.5 mM equally prevented PARP-1-induced mitochondrial depolarization in neuronal death, probably because both identically reversed glycolytic inhibition.69 Thus, DNA damage repairing may primarily does less depend on ATP requirement, but inhibition of cellular senescence albeit pyruvate, per se, is an energy substrate in selective conditions. Pyruvate probably as both a NAD+ substitute and a novel senolytic agent may be more beneficial than NAD+/senolytics, per se, due to its multifactorial salutary protection of cell function, including DNA repairing in different molecular mechanisms from NAD+ (Table 1).7,47

Several pieces of evidence have displayed the pyruvate protection of DNA repairing in rat hepatocytes and mouse and human skin cells.47,70,71 However, no research work compares pyruvate to senolytics in this context. It is valuable to differentiate effects of NAD+ or senolytics from pyruvate on cellular senescence in DNA damage repairing and cell survival and to explore underlying molecular mechanisms on an equimolar basis in various pathogenic assaults and healthy aging.

Importantly, a recent study indicated that the impaired NAD+ metabolism in diabetes lead to adverse effects from NAD+ and its precursors.72 Thus, chronic oral pyruvate may be advantageous over NAD+ supplementation in diabetes patients for healthy aging. Further studies are urgently required in comparison of NAD+ to pyruvate in the elderly with or without diabetes. In fact, pyruvate clinical trials are recently recommended.73,74 It is worthy of note that the acidic pyruvate aqueous solution is long-term stable and pyruvate as a dietary supplement is permitted according to US FAD documents.48,75

Intriguingly, ethyl pyruvate (EP, a pyruvate derivative), a well-known high mobility group box 1 (HMGB1, an inflammatory cytokine in later stages) inhibitor, also reversed the senescent phenotype of bone marrow-mesenchymal stem cells from MRL/lpr (Lupus) mice. Further, it alleviated the pathological alterations of lupus nephritis (significant reduction of albuminuria and renal histological changes) and prolonged survival of the mice.76 It was newly further demonstrated that EP with glycyrrhizic acid through the inhibition of HMGB1 release and inflammatory senescence prevented Tau oligomers-induced cellular senescence and tauopathies, such as Alzheimer’s disease, in the brain of mice.77 In this regard, EP was recently proposed in Covid-19 treatments,78 as mentioned above due to susceptibility of cellular senescence to viral infection.37 Similarly, pyruvate is also brain protective against tauopathy and sodium pyruvate was hypothesized in the intervention of Covid-19 viral infection, too.46,75

Data from EP additionally support pyruvate effects on eliminating cellular senescence in animal studies and encourage clinical applications of pyruvate-enriched resuscitation fluids, including IV solutions and oral rehydration salt (Pyr-ORS) in diseases and healthy aging because EP does not work in humans.48,64 IV pyruvate solutions would be superior to current fluids in critical care patients with various severe pathogenic injuries in reversal of lethal hypoxic lactic acidosis and diabetic ketoacidosis, improving survival.41,42,75 Given the clinical safety with large doses of oral or IV pyruvate administration in severe diseases, such as diabetes and mitochondriopathy, oral pyruvate in Pyr-ORS to efficiently enhance pyruvate absorption from intestine may be preferably as a functional beverage for anti-diabetes and -aging in a large population.4,48,75,79 However, current evidence of pyruvate eradication of cellular senescence and exertion of senolytic effects is still limited and largely underdeveloped. Further studies are warranted, particularly lying on the blood effective pyruvate levels absorbed from enteral pyruvate.48 Nevertheless, it would be hopeful that the salutary effect of oral pyruvate-enriched fluids for healthy aging is feasible and practicable with clinical safety and low cost.48,79

“Strengthening research, data, and innovation” is one of topics in the United Nations (UN) Decade of Healthy Ageing (2021-2030) that was just launched.80 Pyruvate may play a specific role in preventing diseases and improving healthy aging in the UN Decade.

Conclusion
Albert numerous investigations demonstrate that NAD+ in its precursors and senolytics are protective against diseases and aging, current studies indicate that pyruvate as one of novel senolytics besides a NAD+ substitute may be a potent agent. Oral Pyr-ORS and IV pyruvate-enriched fluids as a potential nutraceutical intervention may be more beneficial with clinical safety relative to current products in nutrition markets for diseases and healthy aging. Further research and clinical trials to compare pyruvate with NAD+, senolytics, specifically on the equimolar basis, or their combination in healthy aging are required.

Author Note
The opinions or assertions contained herein are not a reflection of the view of Fresenius Medical Care, Dialysis Centers in Chicago, Illinois.

Acknowledgements
The author heartedly thanks to Dr. Xu M, Mayo Clinic, Rochester, MN, for his suggestion in the manuscript preparation. The author also very appreciates reviewers’ critical comments.
Author contribution FQZ prepared the manuscript draft and completed the revised version following the reviewer’s comment.

ORCID iD
Fang-Qiang Zhou https://orcid.org/0000-0003-1967-6943

REFERENCES
1. Katsyuba E, Romani M, Hofer D, Auwers J. NAD+ homeostasis in health and disease. Nat Metab. 2020;2:9–31.
2. Kang BE, Choi JY, Stein R, Ryu D. Implications of NAD+ boosters in transla-
tional medicine. Eur J Clin Invest. 2020;50:e13334.
3. Wang Y, Huang Y, Yang J, Zhou FQ, Zhao L, Zhou H. Pyruvate is a prospective
aldehyde to correct hyperoxic lactic acidosis. Mil Med Res. 2018;5:13.
4. Zhang XM, Deng H, Tong JD, et al. Pyruvate-enriched oral rehydratesolu-
tion improves glucometabolic disorders in the kidneys of diabetic db/db mice. J Diabetes Res. 2020;2020:2817972.
5. Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD homeostasis in health and
disease. Nature. 2020;578:411–412.
6. Zhang XM, Deng H, Tong JD, et al. Pyruvate-enriched oral rehydration solu-
tion improves glucometabolic disorders in the kidneys of diabetic db/db mice. J Diabetes Res. 2020;2020:2817972.
7. Li J, Bonkowski MS, Moniot S, et al. A conserved NAD+ binding pocket
that regulates protein-protein interactions during aging. Science. 2017;355:1312–1317.
8. Tarantini S, Valcarcel-Ares MN, Torp P, et al. Nicotinamide mononucleotide
(NMN) supplementation rescues cerebrovascular endothelial function and
neurovascular coupling responses and improves cognitive function in aged mice. Redox Biol. 2019;24:101192.
9. Shi B, Wang W, Korman B, et al. Targeting CD38-dependent NAD+ metabo-
43. Liu R, Wang SM, Liu XQ, et al. Pyruvate alleviates lipid peroxidation and
44. Li M, Zhou S, Chen C, et al. Therapeutic potential of pyruvate therapy for
45. Han C, Yang H, Li B, Wang Z. Exogenous pyruvate facilitates ultraviolet
46. Koivisto H, Leinonen H, Puurula M, et al. Corrigendum: chronic pyruvate sup-
47. Han C, Yang H, Li B, Wang Z. Exogenous pyruvate facilitates ultraviolet
48. Koivisto H, Leinonen H, Puurula M, et al. Corrigendum: chronic pyruvate sup-
49. Han C, Yang H, Li B, Wang Z. Exogenous pyruvate facilitates ultraviolet
50. Mateva L, Petkova I, Petrov K, et al. Ten-day course of sodium pyruvate infu-
51. Petkova I, Mateva L, Beniozef D, Petrov K, Thorn W. Sodium pyruvate infu-
52. Petkova I, Hristov V, Petrov K, Thorn W. Oral application of sodium pyruvate in
53. Santin Y, Luel D, Pirsigk J, Gamé X, Milet-Perez J, Parini A. Cellular senes-
cence in renal and urinary tract disorders. Cells. 2020;9:2420.
54. Dookun E, Walaszczyk A, Redgrave R, et al. Clearance of senescent cells during
55. Xu M, Pirtskhalava T, Farr JN, et al. Senolytics improve physical function and
increase lifespan in old age. Nat Med. 2018;24:1246–1256.
56. Martyrano V, Kim GJ, Hayes W, et al. Novel lung imaging biomarkers and skin
expression subsetting in dasatinib treatment of systemic sclerosis-associated
intestinal lung disease. PlaSOn. 2017;12.e0187580.
57. Martyrano V, Whitfield ML, Varga J. Senescence signature in skin biopsies
from systemic sclerosis patients treated with senolytic therapy: potential predic-
tors of clinical response. Arthritis Res Ther. 2019;21:1766–1767.
58. Lehmann M, Korfei M, Mutze K, et al. Senolytic drugs target alveolar epithelial
cell function and attenuate experimental lung fibrosis ex vivo. Eur Respir J. 2017;50:162367.
59. Xu M, Pirskkalvo T, Farr JN, et al. Senolytics improve physical function and
increase lifespan in old age. Nat Med. 2018;24:1246–1256.
60. Hickson LJ, Langhi Prata LGP, Bobart SM, et al. Senolytics decrease senescent
cells in humans: preliminary report from a clinical trial of Dasatinib plus Quer-
cetin in individuals with diabetic kidney disease. EBioMedicine. 2019;47:446–456.
61. Palmer AK, Xu M, Zha Y, et al. Targeting senescent cells alleviates obesity-
induced metabolic dysfunction. Aging Cell. 2019;18:12950.
62. Doonk E, Walaszczyk A, Redgrave R, et al. Clearance of senescent cells during
cardiac ischemia-reperfusion injury improves recovery. Aging Cell. 2020;19:e13249.
63. Coryell PR, Diekman BO, Losser RF. Mechanisms and therapeutic implica-
tions of cellular senescence in osteoarthrithis. J Rheumatol. 2021;37:47–57.
64. Santin Y, Luel D, Pirsigk J, Gamé X, Milet-Perez J, Parini A. Cellular senes-
cence in renal and urinary tract disorders. Cells. 2020;9:2420.
65. Robinson PD, Jurk D, Khosa S, et al. Senolytic drugs: reducing senescence
cell burden to extend health span. Annu Rev Pharmacol Toxicol. 2021;61:779–803.
66. Salehi B, Machin L, Monzote L, et al. Therapeutic potential of quercetin: new
insights and perspectives for human health. ACS Omega. 2020;5:11849–11872.
67. Derosa G, Maffioli P, D’Angelo A, Di Piro F. A role for quercetin in coronavi-
rus disease 2019 (COVID-19). Front Immunol. 2020;11:e122860.
68. Malavolta M, Giacconi R, Brunetti D, Provinciali M, Maggi F. Exploring the
relevance of senotherapeutics for the current SARS-COV-2 emergency and simi-
lar future global health threats. Cells. 2020;9:909.
69. Nehme J, Borgehan S, Mackedenski S, Bird TG, Demaria M. Cellular senes-
cence as a potential mediator of COVID-19 severity in the elderly. Aging Cell. 2020;19:e13237.
70. Camell CD, Yousefzadeh MJ, Zhu Y, et al. Senolytics reduce coronavirus-related
mortality in old mice. Science. 2021;373:eabe4832.
71. Hu S, Bai XD, Liu XQ, et al. Pyruvate ringer’s solution corrects lactic acidosis
and prolongs survival during hemorrhagic shock in rats. J Emerg Med. 2021;55:885–893.
72. Flaherty DC, Hocho B, Sun J, et al. Pyruvate-fortified fluid resuscitation
improves hemodynamic stability while suppressing systemic inflammation and
myocardial oxidative stress after hemorrhagic shock. Mil Med. 2019;175:166–172.
73. Liu R, Wang SM, Liu XQ, et al. Pyruvate alleviates lipid peroxidation and mul-
tiple-organ dysfunction in rats with hemorrhagic shock. Am J Emerg Med. 2016;34:525–530.
74. Li M, Zhou S, Chen C, et al. Therapeutic potential of pyruvate therapy for
patients with mitochondrial diseases: a systematic review. Ther Adv Endocrinol Metab. 2020;11:204018820938240.
75. Zhang XM, Wang YZ, Tong JD, et al. Pyruvate alleviates high glucose-induced
endoplasmic reticulum stress and apoptosis in HK-2 cells. FEBS Open Bio. 2019;10:827–834.
76. Koivisto H, Leinonen H, Puurula M, et al. Corrigendum: chronic pyruvate sup-
plementation increases exploratory activity and brain energy reserves in young
and middle-aged mice. Front Aging Neurosci. 2017;9:67. Erratum for: Front Aging Neurosci. 2016;8:41.
77. Han C, Yang H, Li B, Wang Z. Exogenous pyruvate facilitates ultraviolet
B-induced DNA damage repair by promoting H3K9 acetylation in keratinocytes and
melanocytes. BioMed Pharmacother. 2020;126:110082.
78. Zhou FQ, Pyruvate research and clinical application outlooks a revolutionary
medical advance. Int J Nutr. 2020;5:1–9.
79. Schilling W, Hanisch M, Sossalla S, Hermann HP, Hasenfuss G. Intracoro-
ary pyruvate in cardiac shock as an adjunctive therapy to catecholamines and
intra-aortic balloon pump shows beneficial effects on hemodynamics. Clin Res Cardiol. 2011;100:433–438.
80. Mateeva L, Petkova I, Petrov K, et al. Ten-day course of sodium pyruvate sup-
usions in patients with idiopathic pulmonary diseases (CLD). Ipn Pharmaceut. Ther. 1996;24:2629–2639.
81. Petkova I, Mateeva L, Beniozef D, Petrov K, Thorn W. Sodium pyruvate sup-
usions in patients with alcoholic liver disease. Preliminary report. Acta Physiol Pharmacol Bulg. 2000;25:103–108.
82. Petkova I, Hristov V, Petrov K, Thorn W. Oral application of sodium pyruvate in healthy persons and patients with diabetes mellitus type 1. Comptes Rendus de l'Academie Bulgare Des Sci. 2007;60:579–584.
53. Inoue T, Murakami N, Ayabe T, et al. Pyruvate improved insulin secretion status in a mitochondrial diabetes mellitus patient. J Clin Endocrinol Metab. 2016;101:1924–1926.

54. Koga Y, Povalko N, Inoue E, Nashiki K, Tanaka M. Biomarkers and clinical rating scales for sodium pyruvate therapy in patients with mitochondrial disease. Mitochondrion. 2019;48:11–15.

55. Sheline CT, Cai AL, Zhu J, Shi C. Serum or target deprivation-induced neuronal death causes oxidative neuronal accumulation of Zn\(^{2+}\) and loss of NAD\(^{+}\). Eur J Neurosci. 2010;32:894–904.

56. Mongan PD, Karaian J, Van Der Schuur BM, Va DK, Sharma P. Pyruvate prevents poly-ADP ribose polymerase (PARP) activation, oxidative damage, and pyruvate dehydrogenase deactivation during hemorrhagic shock in swine. J Surg Res. 2003;112:180–188.

57. Liu N, Wu YG, Lan GC, et al. Pyruvate prevents aging of mouse oocytes. Reproduction. 2009;138:223–234.

58. Yoshino J, Mills KF, Yoon MJ, Imai S. Nicotinamide mononucleotide, a key NAD\(^{+}\) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab. 2011;14:528–536.

59. Chen CN, Lin SY, Liao YH, Li ZJ, Wong AM. Late-onset caloric restriction alters skeletal muscle metabolism by modulating pyruvate metabolism. Am J Physiol Endocrinol Metab. 2015;308:E942–E949.

60. Gou D, Tan H, Cai H, Zhou F. Pyruvate effects on red blood cells attenuates liver injury in a murine transfusion model. Mediators Inflamm. 2016;2016:3549207.

61. Xia S, Chen G, Wang B, et al. Addition of sodium pyruvate to stored red blood cells attenuates liver injury in a murine transfusion model. Mediators Inflamm. 2016;2016:3549207.

62. Kiselevsk-Reding H, Peterson C, Gibson GE. The pyruvate dehydrogenase complex during aging. Mech Ageing Dev. 1984;26:67–73.

63. Stacpoole PW. The pyruvate dehydrogenase complex as a therapeutic target for age-related diseases. Aging Cell. 2012;11:371–377.

64. Zhou FQ. Pyruvate may be a novel intervention of diabetes. Interv Obes Diab. 2021;5:415–418.

65. Kaplon J, Zheng L, Meissl K, et al. A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. Nature. 2013;498:109–112.

66. Olenchock BA, Vander Heiden MG. Pyruvate as a pivot point for oncogene-induced senescence. Cell. 2013;153:1429–1430.

67. Kim YJ, Lee SH, Bae IH, et al. Pyruvate protects against cellular senescence through the control of mitochondrial and lysosomal function in dermal fibroblasts. J Invest Dermatol. 2018;138:2522–2530.

68. Iannetti EF, Smektintik JAM, Willems PHGM, Beyrath J, Koopman WJH. Rescue from galactose-induced death of Leigh syndrome patient cells by pyruvate and NAD\(^{+}\). Cell Death Dis. 2018;9:1135.

69. Alano CC, Garnier P, Ying Y, Higashi Y, Kauppinen TM, Swanson RA. NAD\(^{+}\) depletion is necessary and sufficient for poly(ADP-ribose) polymerase-1-mediated neuronal death. J Neurosci. 2010;30:2967–2978.

70. McGowan JA, Büchler NL. Pyruvate promotion of DNA synthesis in serum-free primary cultures of adult rat hepatocytes. In Vitro. 1983;19:159–166.

71. Chenoufi N, Loréal O, Drénou B, et al. Iron may induce both DNA synthesis and repair in rat hepatocytes stimulated by EGF/pyruvate. J Hepatol. 1997;26:650–658.

72. Fan L, Cacicedo JM, Ido Y. Impaired nicotinamide adenine dinucleotide (NAD\(^{+}\)) metabolism in diabetes and diabetic tissues: implications for nicotinamide-related compound treatment. J Diabetes Invest. 2020;11:1403–1419.

73. Maller RT, Olivencia-Yurvati AH, Bünger R. Pyruvate-enriched resuscitation for shock. Exp Biol Med. 2018;243:663–664.

74. Battaglia S, De Santis S, Rutigliano M, et al. Uridine and pyruvate protect T cells’ proliferative capacity from mitochondrial toxic antibiotics: a clinical pilot study. Sci Rep. 2021;11:2841.

75. Zhou FQ. Pyruvate potential effects on Covid-19 virus infection: novel fluid intervention and prevention. Lon J Med Health Res. 2020;20:69–77.

76. Ji J, Fu T, Dong C, et al. Targeting HMGB1 by ethyl pyruvate ameliorates systemic lupus erythematosus and reverses the senescent phenotype of bone marrow-mesenchymal stem cells. Aging (Albany NY). 2019;11:4338–4353.

77. Gaiwad S, Puangmalai N, Bittar A, et al. Tau oligomer induced HMGB1 release contributes to cellular senescence and neuropathology linked to Alzheimer’s disease and frontotemporal dementia. Cell Rep. 2021;36:109419.

78. Tanwar O, Soni A, Prajapat P, et al. Ethyl pyruvate as a potential defense intervention against cytokine storm in Covid-19? ACS Omega. 2021;6:7754–7760.

79. Zhou FQ. Pyruvate-enriched fluids as a novel medical solution and beverage. A novel medical solution and beverage. Int J Vitam Nutr Res. 2016;86:258–265.

80. Rudnicka E, Napierała P, Podfigurna A, Męczekalski B, Smolarczyk R, Grymonwicz M. The World Health Organization (WHO) approach to healthy ageing. Maturitas. 2020;139:6–11.